Study S000912

Exenatide for Myocardial Protection During Reperfusion Study: A Double-blind, Placebo-controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01938235
Acronym: EMPRES
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 198
Start: 2014-02
Primary completion: 2017-07
Lead sponsor: University Health Network, Toronto
Conditions: Myocardial Infarction
Interventions: DRUG:Exenatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED
Secondary identifiers: OTHER:9427-D0416-21C

Registered primary outcomes

Ratio of final infarct size at 3 months over area at risk at 72 hours post randomization (using cMRI) [3 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.